Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219


Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.

Baxter EJ, Kulkarni S, Vizmanos JL, Jaju R, Martinelli G, Testoni N, Hughes G, Salamanchuk Z, Calasanz MJ, Lahortiga I, Pocock CF, Dang R, Fidler C, Wainscoat JS, Boultwood J, Cross NC.

Br J Haematol. 2003 Jan;120(2):251-6.


Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM.

N Engl J Med. 2002 Aug 15;347(7):481-7.


Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).

Kulkarni S, Heath C, Parker S, Chase A, Iqbal S, Pocock CF, Kaeda J, Cwynarski K, Goldman JM, Cross NC.

Cancer Res. 2000 Jul 1;60(13):3592-8.


Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.

Walz C, Metzgeroth G, Haferlach C, Schmitt-Graeff A, Fabarius A, Hagen V, Prümmer O, Rauh S, Hehlmann R, Hochhaus A, Cross NC, Reiter A.

Haematologica. 2007 Feb;92(2):163-9.


Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib.

Wilkinson K, Velloso ER, Lopes LF, Lee C, Aster JC, Shipp MA, Aguiar RC.

Blood. 2003 Dec 1;102(12):4187-90. Epub 2003 Aug 7.


Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.

Gallagher G, Horsman DE, Tsang P, Forrest DL.

Cancer Genet Cytogenet. 2008 Feb;181(1):46-51. doi: 10.1016/j.cancergencyto.2007.10.021.


HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2).

Morerio C, Acquila M, Rosanda C, Rapella A, Dufour C, Locatelli F, Maserati E, Pasquali F, Panarello C.

Cancer Res. 2004 Apr 15;64(8):2649-51.


Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R, Gardembas M, Goldman JM, Grand F, Hughes G, Huguet F, Lavender L, McArthur GA, Mahon FX, Massimini G, Melo J, Rousselot P, Russell-Jones RJ, Seymour JF, Smith G, Stark A, Waghorn K, Nikolova Z, Apperley JF.

Blood. 2007 Jan 1;109(1):61-4. Epub 2006 Sep 7.


TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13).

Wlodarska I, Mecucci C, Marynen P, Guo C, Franckx D, La Starza R, Aventin A, Bosly A, Martelli MF, Cassiman JJ, et al.

Blood. 1995 May 15;85(10):2848-52.


Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).

Walz C, Haferlach C, Hänel A, Metzgeroth G, Erben P, Gosenca D, Hochhaus A, Cross NC, Reiter A.

Genes Chromosomes Cancer. 2009 Feb;48(2):179-83. doi: 10.1002/gcc.20629.


H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22).

Schwaller J, Anastasiadou E, Cain D, Kutok J, Wojiski S, Williams IR, LaStarza R, Crescenzi B, Sternberg DW, Andreasson P, Schiavo R, Siena S, Mecucci C, Gilliland DG.

Blood. 2001 Jun 15;97(12):3910-8.


Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.

Gosenca D, Kellert B, Metzgeroth G, Haferlach C, Fabarius A, Schwaab J, Kneba M, Scheid C, Töpelt K, Erben P, Haferlach T, Cross NC, Hofmann WK, Seifarth W, Reiter A.

Genes Chromosomes Cancer. 2014 May;53(5):411-21.


Molecular cytogenetic findings in a four-way t(1;12;5;12)(p36;p13;q33;q24) underlying the ETV6-PDGFRB fusion gene in chronic myelomonocytic leukemia.

Crescenzi B, La Starza R, Nozzoli C, Ciolli S, Matteucci C, Romoli S, Rigacci L, Gorello P, Bosi A, Martelli MF, Marynen P, Mecucci C.

Cancer Genet Cytogenet. 2007 Jul 1;176(1):67-71.


Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.

Naumann N, Schwaab J, Metzgeroth G, Jawhar M, Haferlach C, Göhring G, Schlegelberger B, Dietz CT, Schnittger S, Lotfi S, Gärtner M, Dang TA, Hofmann WK, Cross NC, Reiter A, Fabarius A.

Genes Chromosomes Cancer. 2015 Dec;54(12):762-70. doi: 10.1002/gcc.22287. Epub 2015 Sep 10.


Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms.

Hidalgo-Curtis C, Apperley JF, Stark A, Jeng M, Gotlib J, Chase A, Cross NC, Grand FH.

Br J Haematol. 2010 Jan;148(2):268-73. doi: 10.1111/j.1365-2141.2009.07955.x. Erratum in: Br J Haematol. 2010 Mar;148(6):964. Stark, Anthony [corrected to Stark, Allistair].


Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.

Cavazzini F, Bardi A, Ciccone M, Rigolin GM, Gorello P, La Starza R, Mecucci C, Cuneo A.

Cancer Genet Cytogenet. 2009 Oct;194(1):67-9. doi: 10.1016/j.cancergencyto.2009.04.026. No abstract available.


Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.

Pardanani A, Tefferi A.

Blood. 2004 Oct 1;104(7):1931-9. Epub 2004 May 27. Review.


KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).

Levine RL, Wadleigh M, Sternberg DW, Wlodarska I, Galinsky I, Stone RM, DeAngelo DJ, Gilliland DG, Cools J.

Leukemia. 2005 Jan;19(1):27-30.


Supplemental Content

Support Center